ALZpath Announces Appointment of Chad Holland as President and Chief Executive Officer
Company Co-founder Venkat Shastri to Remain Active in Advisory Role CARLSBAD, CA, July 9, 2024 – ALZpath, Inc., a leading developer of innovative diagnostic tools and solutions for Alzheimer’s disease and related dementias, today announced the board’s appointment of Chad Holland as the company’s new president and CEO. The appointment comes after Venkat Shastri, company […]
ALZpath Announces Licensing Agreement with Roche for Use of ALZpath’s Proprietary pTau217 Antibody in Blood Test to Diagnose Alzheimer’s Disease
Agreement Paves the Way for New Era of Accessible, Precise, and Reliable Diagnostic Blood Tests Capable of Identifying Alzheimer’s Disease in its Earliest Stages CARLSBAD, California, June 10th, 2024 — ALZpath, Inc. (ALZpath), a leading developer of innovative diagnostic tools and solutions for Alzheimer’s disease and related dementias, today announced a strategic license agreement with Roche […]
Alamar Biosciences and ALZpath, Inc. Announce Strategic Supply Agreement for pTau217 Antibody to Advance Alzheimer’s Disease Research
CARLSBAD, Calif., — February 29th, 2024 — ALZpath, Inc. (ALZpath), Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, is pleased to announce a strategic supply agreement with ALZpath, a leading developer of diagnostic solutions in Alzheimer’s disease and related dementias. This collaboration marks a significant milestone in the advancement […]
New Study Published in JAMA Neurology Affirms High Diagnostic Accuracy of ALZpath’s pTau217 Test in Identifying Amyloid and Tau in the Brain
ALZpath’s Blood-Based Test Delivers Accuracy Comparable to More Invasive and Expensive CSF-Based Tests, Reducing the Need for Confirmatory Testing By ~80% CARLSBAD, Calif., — January 22, 2024 — ALZpath, Inc. (ALZpath), a leader in Alzheimer’s diagnostics, announced new findings published online today in JAMA Neurology showing that its proprietary blood-based biomarker assay for phosphorylated tau […]
ALZpath Announces New Funding from the Alzheimer’s Drug Discovery Foundation (ADDF) to Advance a Novel, Diagnostic Blood-Based Assay
Funding will accelerate the analytical and clinical validation of ALZpathDx, a proprietary assay for quantifying phosphorylated tau 217 (pTau217), a highly accurate diagnostic biomarker for Alzheimer’s disease. Carlsbad, CA – July 18, 2023 – ALZpath, a leading developer of innovative diagnostic solutions for Alzheimer’s disease, is proud to announce that they have received funding from […]
ALZpath Inc., an Alzheimer’s Disease Diagnostics and Patient Services Company Announces Novel Validated and Scalable Assay for Detection of Phosphorylated Tau 217 in Blood
Carlsbad, Calif., Nov. 28, 2022 – ALZpath, Inc. announced today the launch of its first diagnostic assay for detection of phosphorylated tau 217 (pTau217) in blood. pTau217 is widely considered to be one of the leading transformative Alzheimer’s disease (AD) diagnostic biomarkers by enabling earlier and more accurate AD diagnoses, better stratifying patients for clinical […]